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Abstract
Purpose—In the randomized phase III trial, Gynecologic Oncology Group protocol 240, the 
incorporation of bevacizumab with chemotherapy significantly increased overall survival (OS) in 
women with advanced cervical cancer. A major objective of GOG-240 was to prospectively 
analyze previously identified pooled clinical prognostic factors known as the Moore criteria.
Experimental Design—Potential negative factors included black race, performance status 1, 
pelvic disease, prior cisplatin, and progression-free interval <365 days. Risk categories included 
low-risk (0-1 factor); intermediate-risk (2-3 factors); high-risk (4-5 factors). Each test of 
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association was conducted at the 5% level of significance. Logistic regression and survival 
analysis was used to determine whether factors were prognostic or could be used to guide therapy.
Results—For the entire population (n=452), high-risk patients had significantly worse OS 
(p<0.0001). The hazard ratios of death for treating with topotecan in low-risk, mid-risk, and high-
risk subsets are 1.18 (95% CI 0.63-2.24), 1.11 (95% CI 0.82-1.5), and 0.84 (95% CI 0.50-1.42), 
respectively. The hazard ratios of death for treating with bevacizumab in low-risk, mid-risk, and 
high-risk subsets are 0.96 (95% CI 0.51-1.83; p=0.9087), 0.673 (95% CI 0.5-0.91; p=0.0094), and 
0.536 (95% CI 0.32-0.905; p=0.0196), respectively.
Conclusions—This is the first prospectively validated scoring system in cervical cancer. The 
Moore criteria have real world clinical applicability. Toxicity concerns may justify omission of 
bevacizumab in some low-risk patients where survival benefit is small. The benefit to receiving 
bevacizumab appears to be greatest in the moderate- and high-risk subgroups (5.8 month increase 
in median OS).
Keywords
cervical cancer; prognostic factors; scoring system; antiangiogenesis therapy
Introduction
Women with recurrent and metastatic cervical cancer constitute a population for whom 
treatment options have been extremely limited (1). With sophisticated radiotherapy planning 
and concurrent chemotherapy for radiosensitization and sterilization of occult metastatic 
tumor foci, central control can be achieved which indirectly eliminates candidacy for pelvic 
exenteration to clear recurrent tumor (2). In those cases when central failure occurs it is 
commonly accompanied by distant failure which also abrogates any curative intent of 
exenteration. Previously, chemotherapy using cisplatin plus paclitaxel in these settings had 
been palliative, with rapid clinical deterioration, worsened quality of life (QoL), and median 
overall survival (OS) ranging from 7-12 months (3,4). Importantly, many patients with 
recurrent disease have been pre-irradiated with limited bone marrow reserves, and may be 
platinum-resistant as a consequence of prior platinum exposure with radiotherapy and 
subsequent acquired drug resistance (5,6). In addition, many are medically infirm due to 
renal failure and malnutrition.
Gynecologic Oncology Group (GOG) 240 was developed to study the non-platinum 
chemotherapy doublet, topotecan plus paclitaxel, as well as anti-angiogenesis therapy (7). 
Vascular endothelial growth factor (VEGF) has emerged as an important therapeutic target 
and the monoclonal anti-VEGF humanized antibody, bevacizumab, was found to be active in 
GOG-227C, a phase II trial in heavily pretreated patients with recurrent cervical cancer (8). 
The primary endpoint of GOG-240 was OS.
In February 2013, the National Cancer Institute (NCI) and the GOG issued a Press Release 
stating that compared to chemotherapy alone, the incorporation of bevacizumab led to 
significantly improved OS (17m vs 13.3m) and progression-free survival (PFS) (8.2m vs. 
5.9m) (9). The integration of bevacizumab also significantly improved response rate (RR) 
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(48% vs. 36%) without a significant deterioration in health-related QoL (9,10). On March 
10, 2014, the Cancer Drugs Fund approved bevacizumab for women in England with 
advanced cervical cancer. Following U.S. FDA approval of bevacizumab for advanced 
cervical cancer on August 14, 2014, the NCCN has listed both triplet regimens studied (i.e. 
cisplatin-paclitaxel-bevacizumab and topotecan-paclitaxel-bevacizumab) as Category 1 (11).
A major objective in GOG 240 was to prospectively study previously identified pooled 
prognostic factors known as the Moore criteria (12). If risk stratification were to be validated 
in the GOG-240 population, two important questions could be asked. First, could risk 
stratification be used to guide therapy, i.e., to select the optimal chemotherapy backbone? 
Secondly, does risk stratification identify a cohort that is unsuitable for “standard” therapy 
due to a low likelihood for response?
Methods
Eligibility Criteria, Study Design, and Treatment
GOG-240 was a phase III randomized trial conducted through the GOG and the Spanish 
cooperative group, Grupo Español de Investigation en Cancer de Ovario (GEICO) with NCI-
supplied bevacizumab (NSC #704865, IND #113912), with central IRB approval and 
registration (NCT00803062), signed informed consent, and central pathology review (9). 
Primary endpoints were OS and the frequency and severity of toxicity and secondary 
endpoints were PFS and RR (9). Prospective validation of the Moore criteria of pooled poor 
prognostic factors and quality of life were tertiary endpoints. Eligibility required primary 
Stage IVB or recurrent/persistent cervical carcinoma with measurable disease and GOG 
performance status 0-1 (9). Using a 2×2 factorial design, participants were randomized to 
one of four intravenous regimens: paclitaxel (135 mg/m2 over 24 hours or 175 mg/m2 over 3 
hours) with cisplatin (50 mg/m2) with or without bevacizumab 15 mg/kg, or paclitaxel 175 
mg/m2 over 3 hours on day 1 with topotecan 0.75 mg/m2 over 30 minutes days 1-3 with or 
without bevacizumab 15 mg/kg (Supplemental Figure SF1A). Cycles were repeated every 21 
days until disease progression, unacceptable toxicity, or complete response. Tumor 
measurements were made using Response Evaluation Criteria in Solid Tumors (RECIST v1) 
and safety was assessed by the National Cancer Institute's Common Terminology Criteria 
for Adverse Events. One interim analysis was scheduled at 173 events. A second analysis 
(271 deaths) occurred 11 months later.
Efficacy
At the first interim analysis, the non-platinum chemotherapy doublet, topotecan-paclitaxel, 
was reported to be not superior to the cisplatin-paclitaxel chemotherapy backbone 
(Supplemental Figure SF1B) (9). At the second analysis, the bevacizumab-containing 
regimens were found to have significantly improved OS, PFS, and RR over chemotherapy 
alone (Supplemental Figure SF1C) (9).
Pooled Poor Prognostic Factors: Early Development of the Training Set
The Moore criteria were identified by pooling 20 clinical factors from 429 patients enrolled 
and treated on three prior GOG phase III trials in recurrent/persistent and metastatic cervical 
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cancer (GOG protocols 110, 169, and 179) (12, 13-15). Five factors were prognostic and 
included performance status >0, pelvic disease, African-American ancestry, disease-free 
interval <1 year, and prior platinum exposure.
The factors were weighted equally and confirmed to impart a poor prognosis when applied 
as a training set including low risk (0- 1 factor), mid-risk (2- 3 factors), and high risk (4 or 5 
factors). This training set was retrospectively applied to another prior phase III trial in this 
population (GOG-149) (16).
Pooled poor prognostic factors: Prospective Validation of the Training Set
The Moore criteria were analyzed in the entire study population of GOG-240 to determine 
whether the risk categories had prognostic significance. Next, each chemotherapy backbone 
was studied and compared to determine if the risk categories could guide therapy. Finally, 
the Moore criteria were applied to the subset of patients treated with chemotherapy plus 
bevacizumab to potentially identify a cohort of patients that were likely not to benefit from 
anti-angiogenesis therapy, presumably because their risk stratification was so poor it 
rendered them unsalvageable with contemporary therapy which was defined as 
chemotherapy (either backbone) plus bevacizumab.
Statistical Analysis
Five clinical risk factors were examined for prognostic value with clinical outcome variables 
(OS, PFS, RR). The variables examined were race (African ancestry or not), performance 
status (1 or 0), measurable disease in the pelvis (yes/ no), prior platinum as a radiation 
sensitizer (yes/ no), and progression-free interval from diagnosis of disease (≤365 days or 
>365 days). Associations with response were assessed with logistic models whereas 
associations with PFS and OS were assessed with Cox Proportional Hazard models (17). 
Internal validity of the model was assessed by analyzing the total number of negative risk 
factors as a continuous variable which was found to be highly significant with a hazard of 
progression 1.204 (95% CI, 1.088-1.332) and a hazard of death of 1.480 (1.313-1.668).
Each factor was assessed as univariate components in separate models and together in joint 
models. Total risk score was calculated by adding the number of risk factors to derive a risk 
classifier. The risk class was assessed for both prognostic and predictive value using logistic 
and Cox models. The predictive value was evaluated using an interaction term with 
treatment (cisplatin or topotecan; administration or non-administration of bevacizumab) to 
assess for significance and describe any potential impact.
Results
Using GOG 240 data, the five risk factors were examined separately and in joint models to 
assess the strength of association with clinical outcome. All of the risk factors appeared to 
be detrimental as indicated by their odds ratio estimates being less than 1 even when not 
statistically significant (Table 1).
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Validation of Moore criteria in entire GOG-240 population (arms 1+2+3+4)
The total risk score integrated all of the risk factors into a single statistic, as was done in the 
original publication (12). Application of the Moore criteria to the entire GOG-240 study 
population (i.e., arms 1-4 combined) placed the majority of patients in the mid-risk class 
(n=303, 67%) (Figure 1). Low-risk patients account for 19% (n=84) and high-risk patients 
comprise 14% (n=65) of the study population. The distribution of OS, PFS, and RR mirror 
the low-, mid-, and high-risk subgroup stratification in the direction of statistically 
significant declination for all three endpoints as one moves from low risk to high risk 
(Figure 1). For example, patients with 0 or 1 high risk factor (i.e., low-risk cohort) 
experience 21.8 months OS and 57% RR, while those in the high-risk cohort (4 or 5 factors) 
have significantly worse OS of 8.2 months (p<0.0001) and 18.5% RR (p<0.001).
Patients treated with the topotecan-paclitaxel backbone (arms 3+4)
Using the Moore criteria, analysis of the 223 patients randomized to the topotecan-paclitaxel 
backbone assigns the majority of patients to the mid-risk class (n=151). As one moves from 
low-risk to high-risk classes, OS significantly decreases from 20.1 months to 8.2 months 
(p=0.017). The effect on PFS, while not statistically significant, also deteriorates with 
increasing risk stratification (p=0.066).
Patients treated with bevacizumab (arms 2+4)
Analysis of the 227 patients randomized to the regimens administering bevacizumab places 
the majority (n=152) in the mid-risk class. From low-risk to high-risk subgroups, OS 
decreases from 22.9 months to 12.1 months, respectively (P=0.0513). The declination of 
PFS from low-risk to high-risk is not significant (p=0.1417).
Risk stratification of chemotherapy backbones (arms 1+2 vs 3+4)
The Moore criteria and risk assignment were used to determine whether there exists a 
preferential benefit for patients to be treated with one or the other chemotherapy backbone. 
Treatment with the topotecan-paclitaxel chemotherapy backbone was not a significant 
predictor of OS, PFS, or RR. While the Moore criteria themselves are highly prognostic for 
OS, PFS, and RR, there is no evidence of interaction between the topotecan-paclitaxel 
backbone and the Moore criteria for OS, PFS, or response (Table 2). The estimates of the 
hazard ratios of death for treating with topotecan to cisplatin in the low-risk, mid-risk, and 
high-risk subsets are 1.18 (95% CI 0.63-2.24), 1.11 (95% CI 0.82-1.5), and 0.84 (95% CI 
0.50-1.42), respectively, suggesting perhaps a modest (but non-significant) benefit for high-
risk patients being treated on the topotecan-paclitaxel backbone. The hazard ratios for PFS 
were likewise 1.15 (95% CI 0.71-1.85), 1.26 (95% 0.98-1.62), and 1.00 (95% CI 0.60-1.67) 
in the low, mid, and high risk groups. The odds ratios for responding to therapy in topotecan 
to cisplatin therapy were 0.43 (95% CI 0.18-1.04) in the low group, 0.67 (95% CI 0.43-1.07) 
in the mid group, and 1.45 (95% CI 0.41-5.16) in the high risk group. None of the 
interaction terms were significant.
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Risk stratification among women treated with chemotherapy alone vs chemotherapy plus 
bevacizumab
Eighty-four patients had 0 or 1 risk factor. When these patients are separated by the 
administration of bevacizumab, the median OS between the groups is very similar (21.8 
months in the chemotherapy alone cohort and 22.9 months in the chemotherapy plus 
bevacizumab cohort, Figure 2A) with a hazard ratio of death estimated at 0.96 (95% CI 
0.51-1.83; p=0.9087). Median PFS was also not significantly different among low-risk 
patients treated with chemotherapy with and without bevacizumab (10.9 vs 8.0 months); 
(HR 0.85 (95% CI 0.53-1.37).
The mid-risk group (2 or 3 factors) contained 303 patients. As expected, the median OS 
declined when compared with the low-risk cohort, but in this subgroup the difference in 
median OS (12.1 months in the chemotherapy alone cohort and 17.9 months in the 
chemotherapy plus bevacizumab cohort) is highly significant with an estimated hazard of 
death of 0.673 (95% CI 0.5-0.91; p=0.0094) (Figure 2B). The estimated hazard ratio for the 
PFS endpoint was 0.694 (95% CI 0.54-0.89; p=0.0047).
Among the 65 patients that had 4 or 5 risk factors, the Moore criteria and high-risk 
stratification class was highly prognostic between chemotherapy cohorts who did not receive 
and did receive bevacizumab. The bevacizumab group had better survival with an estimated 
hazard ratio of death of 0.536 (95% CI 0.32-0.905; p=0.0196) (Figure 2C) and an estimated 
hazard ratio of the PFS endpoint of 0.506 (95% CI 0.277-0.926; p=0.0272).
The odds ratio of response for those treated with bevacizumab to those who were not in the 
low, mid, and high risk class patients were 1.52 (95% CI 0.64-3.64), 1.84 (95% CI 
1.16-2.92), and 1.93 (95% CI 0.52-7.18), respectively.
Discussion
The original impetus to study poor prognostic markers in advanced cervical cancer was to 
identify patients a priori who were unlikely to respond to conventional cytotoxic therapy in 
an effort to avoid administration of futile treatment (18,19). The prognostic model for tumor 
response was based on five similarly weighted factors that did not interact, allowing for an 
index based on the total number of risk factors to be derived (13-15).
The Moore criteria were identified in the platinum or cytotoxic era when antiangiogenic 
agents were not yet employed in randomized clinical trials for cervical cancer patients 
(20-22). One of the major conclusions of the original Moore criteria analysis was that 
because even limited toxicity in the face of non-response to treatment or disease progression 
is unacceptable, then high-risk patients should be spared the toxicity of ineffective therapy 
and instead be considered for best supportive care or investigational trials. Before GOG 240 
was developed, some suggested using the Moore criteria to pull out high-risk patients from 
subsequent phase III studies. However, at that time, the Moore criteria had not been 
prospectively validated and for this reason the scoring system was not used to limit 
eligibility in GOG 240. In GOG 240 we have demonstrated that, compared to high-risk 
patients treated with chemotherapy alone, those high-risk patients who received 
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bevacizumab had a significantly lower hazard of death not only within the high-risk group 
but also compared to those at mid-risk level.
Women with advanced cervical cancer are distinguished by often having been pre-irradiated 
resulting in diminished marrow reserves and a vasculitis that limits adequate drug 
distribution and perfusion into irradiated tumor beds. Concurrent chemoradiation leads to 
acquired drug resistance making cisplatin-based therapies less effective at recurrence. 
Finally, often poor and lacking access to healthcare, this population is marginalized by 
society, medically debilitated, malnourished and with diminished renal function due to 
tumor- and radiation-related hydronephrosis and consequent renal insufficiency/failure. 
Women with recurrent cervical cancer often do not respond to multiple lines of 
chemotherapy as do patients with cancer of other types (e.g., ovary, breast). Additional not-
yet-developed models that include factors such as income level, nutritional status, and/or 
renal function may also have clinical utility,
It is not difficult to understand how performance status, short disease-free interval, pelvic 
disease, and prior cisplatin may impair prognosis. It is less clear how African-American 
ethnicity worsens outcome. African-Americans may have limited access to care with co-
morbidities not reflected in performance status, or they may have biologically worse cervical 
cancers (23-27). Farley et al reported that in an equal access, unbiased, nonracial 
environment such as the military, race is not an independent predictor of survival for patients 
with cervical carcinoma (28). Interestingly, in a GOG ancillary data study in the recurrent 
cervical cancer population, Plaxe et al found that cisplatin-based chemotherapy was better 
tolerated by African American women (29).
Angiogenesis confers a poor prognosis in cervical cancer and a molecular cascade involving 
viral oncoproteins E6 and E7 and their interactions with cellular tumor suppressor gene 
products p53 and pRb leads to increased hypoxia inducible factor-1α and VEGF production 
and angiogenesis (30). Through ligand-binding, bevacizumab, sequesters VEGF and inhibits 
angiogenesis. Although the Moore criteria lack definitive predictive capabilities in 
chemotherapy guidance (i.e., backbone selection with which to integrate bevacizumab), 
there is evidence that the risk model can serve as a surrogate for personalized medicine in 
predicting outcomes among different cohorts treated with bevacizumab.
This risk model is a tool for office practice when counseling patients with advanced disease. 
Prognostic factors can be compiled and an estimation of RR (and median survival) using 
anti-angiogenesis therapy can be provided to an individual patient and her family members. 
Patients with the highest risk stratification (i.e., 4-5 factors) derive the greatest relative 
benefit from bevacizumab (HR 0.536) compared to those patients who are in the mid- (HR 
0.673) or low-risk (HR 0.96) cohorts.
Not all low-risk patients are the same and anticipated toxicity should also be considered 
when counseling patients. For example, in GOG 240, fistula occurred in 8.6% of patients 
treated with bevaiczumab, all of whom had been previously irradiated. Additional risk 
factors for fistula may also include recurrent disease in the irradiated pelvis (with or without 
distant metastases) and persistent disease following chemoradiation. In a low-risk patient 
Tewari et al. Page 7
Clin Cancer Res. Author manuscript; available in PMC 2016 December 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
(0-1 factors) treated with chemoradiation prior to recurrence, the Moore criteria can be used 
to argue against including bevacizumab as the fistula risk is 8.6% with very small survival 
benefit. We must acknowledge that despite a significantly improved OS and subsequent US 
FDA regulatory approval, bevacizumab is not curing patients. Development of a fistula may 
preclude eligibility for participation in a promising immunotherapy clinical trial. When 
taken in this context, a previously irradiated low-risk patient who is carefully counseled may 
reasonably choose to not receive bevacizumab.
Performance status is the one Moore factor that is modifiable through medical, nutritional, 
and possibly spiritual intervention. Eligibility criteria for GOG-240 were more stringent than 
in preceding trials. Previously, great expense and effort had been invested in patients with 
very low likelihood of response. Through optimization of medical co-morbidities, correction 
of malnutrition, improved understanding of renal function with expeditious placement of 
ureteral stents and/or percutaneous nephrostomies, the GOG-240 population was “healthier” 
at enrollment than their predecessors in prior trials. To improve survival, we believed that 
resources (including expensive therapies) are best applied to those who stand the greatest 
chance of benefiting. The identification of a near-4 month window of improved OS without 
significant deterioration of QoL suggests that the disease may lend itself to chronicity. 
Patients deriving benefit (eg., stable disease) but who are intolerable to chemotherapy may 
have the latter drugs peeled away and continue with bevacizumab monotherapy. 
Alternatively, those patients responding to anti-angiogenesis therapy may be considered for 
incorporation of immunotherapy prior to progression. Bevacizumab does not signify the end 
of advanced cervical cancer, but hopefully represents a small step forward in the treatment of 
this devastating disease (Figure 3).
This is the first prospectively validated prognostic scoring system in cervical cancer, a 
disease that is only second to lung and breast in cancer-related mortality worldwide. 
Advanced cervical cancer is not a disease in which “cure” is an issue. Studies such as this 
which help to refine treatment selection in a manner that stratifies patients into risk groups 
for anticipated response to treatment and complications are clinically important. 
Characterization of gene signatures that confer risk and blood-based predictive protein 
signatures obtained from women with durable responses to anti-VEGF therapy are needed. 
Mathematical modeling may be used to combine clinical (i.e., Moore-like) risk factors with 
molecular ones and through assignation of different weights, the predictive capabilities of 
the risk model can be refined further.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Statement of Translational Relevance
The phase III international, multi-center trial, GOG 240, demonstrated a significant 
survival advantage among women treated with chemotherapy plus bevacizumab 
compared with chemotherapy alone, and directly led to US FDA approval of the two 
triplet regimens administering bevacizumab. However, anti-angiogenesis therapy in this 
population may be associated with significant toxicity. Clinical scoring systems may 
allow for risk stratification. The data presented are a prospective validatation of the 
Moore clinical prognostic factor scoring system. This system may be used as a clinical 
instrument to counsel patients regarding their likelihood of response and estimated risk of 
progression and death by cervical cancer when considering adding anti-angiogenesis 
therapy to systemic chemotherapy for recurrent/persistent or metastatic cervical cancer. 
Importantly, based on these data patients at mid- to high-risk may be expected to derive 
the greatest benefit from the integration of bevacizumab to chemotherapy, while the 
benefit conferred to low-risk patients appears to be low.
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Figure 1. 
Prospective validation of the Moore criteria in the GOG 240 study population (n=452).
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Figure 2. 
Kaplan Meier overall survival curves following risk stratification according to the Moore 
criteria among women with advanced cervical cancer treated with chemotherapy with and 
without bevacizumab. Panel A: Low-risk class (0-1 poor prognostic factor). Panel B: Mid-
risk class (2-3 poor prognostic factors). Panel C: High-risk class (4-5 poor prognostic 
factors).
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Figure 3. 
Successive improvement in median overall survival among women with advanced cervical 
cancer. The phase III experience of the Gynecologic Oncology Group (now, part of NRG 
Oncology).
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